Ranger Investment Management L.P. Grows Stake in Option Care Health, Inc. (NASDAQ:OPCH)

Ranger Investment Management L.P. boosted its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 112.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 888,495 shares of the company’s stock after acquiring an additional 470,132 shares during the quarter. Option Care Health accounts for 1.8% of Ranger Investment Management L.P.’s portfolio, making the stock its 26th biggest holding. Ranger Investment Management L.P.’s holdings in Option Care Health were worth $29,933,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. increased its position in shares of Option Care Health by 41.2% during the 3rd quarter. Victory Capital Management Inc. now owns 72,177 shares of the company’s stock valued at $2,335,000 after purchasing an additional 21,065 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Option Care Health during the third quarter valued at approximately $474,000. Amalgamated Bank raised its position in Option Care Health by 4.1% in the third quarter. Amalgamated Bank now owns 113,237 shares of the company’s stock worth $3,663,000 after acquiring an additional 4,495 shares during the period. Swiss National Bank boosted its stake in shares of Option Care Health by 6.3% during the 3rd quarter. Swiss National Bank now owns 395,200 shares of the company’s stock worth $12,785,000 after acquiring an additional 23,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Option Care Health by 16.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,353,112 shares of the company’s stock valued at $76,123,000 after acquiring an additional 332,267 shares during the period. Institutional investors own 98.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on OPCH. Barrington Research reissued an “outperform” rating and set a $38.00 price target on shares of Option Care Health in a report on Wednesday, April 24th. Jefferies Financial Group lifted their price objective on Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, March 4th.

Option Care Health Price Performance

Shares of Option Care Health stock traded up $0.09 during trading hours on Friday, hitting $29.19. The company’s stock had a trading volume of 1,217,773 shares, compared to its average volume of 1,103,266. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.39 and a current ratio of 1.77. Option Care Health, Inc. has a 12-month low of $26.17 and a 12-month high of $35.74. The business has a 50 day moving average price of $30.26 and a two-hundred day moving average price of $31.48. The company has a market cap of $5.07 billion, a PE ratio of 19.20, a PEG ratio of 1.42 and a beta of 1.31.

Option Care Health (NASDAQ:OPCH) last issued its earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. Option Care Health’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.21 earnings per share. Analysts expect that Option Care Health, Inc. will post 1.19 earnings per share for the current fiscal year.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.